Product Information
Registration Status: ActiveNEWPORINE CAPSULE 250mg is approved to be sold in Singapore with effective from 1998-08-14. It is marketed by ZIWELL MEDICAL (S) PTE LTD, with the registration number of SIN09940P.
This product contains Cefaclor 250mg in the form of CAPSULE. It is approved for ORAL use.
This product is manufactured by KOREA UNITED PHARMACEUTICAL INC in KOREA, and in REPUBLIC OF.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.
Indication
For the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.
Mechanism of Action
Cefaclor, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. It is possible that cefaclor interferes with an autolysin inhibitor.
Pharmacokinetics
- Absorption
- Well absorbed after oral administration, independent of food intake.
- Distribution
- Metabolism
- No appreciable biotransformation in liver (approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours).
- Elimination
Toxicity
Symptoms of overdose include diarrhea, nausea, stomach upset, and vomiting.
Active Ingredient/Synonyms
3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid | CCL | Cefaclor | Cefaclor anhydrous | Cefacloro | Cefaclorum | Céfeaclor | Cephaclor | Cefaclor |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.